Total Valuation
Hyundai Pharmaceutical Co., Ltd. has a market cap or net worth of ₩156.75B. The enterprise value is ―.
Market Cap₩156.75B
Enterprise Value―
Share Statistics
Hyundai Pharmaceutical Co., Ltd. has 32,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding32,000,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Hyundai Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 2.36%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)2.36%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee480.69M
Profits Per Employee6.31M
Employee Count399
Asset Turnover1.15
Inventory Turnover3.48
Valuation Ratios
The current PE Ratio of Hyundai Pharmaceutical Co., Ltd. is 32.9. Hyundai Pharmaceutical Co., Ltd.’s PEG ratio is -0.07.
PE Ratio32.9
PS Ratio0.50
PB Ratio1.17
Price to Fair Value1.17
Price to FCF-20.26
Price to Operating Cash Flow51.56
PEG Ratio-0.07
Income Statement
In the last 12 months, Hyundai Pharmaceutical Co., Ltd. had revenue of 191.79B and earned 2.52B in profits. Earnings per share was 96.28.
Revenue191.79B
Gross Profit78.23B
Operating Income3.30B
Pretax Income2.31B
Net Income2.52B
EBITDA7.58B
Earnings Per Share (EPS)96.28
Cash Flow
In the last 12 months, operating cash flow was 3.21B and capital expenditures -3.51B, giving a free cash flow of -292.44M billion.
Operating Cash Flow3.21B
Free Cash Flow-292.44M
Free Cash Flow per Share-9.14
Dividends & Yields
Hyundai Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.67
52-Week Price Change45.23%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)6.64M
Important Dates
Hyundai Pharmaceutical Co., Ltd. upcoming earnings date is Oct 19, 2026, TBA (Confirmed).
Last Earnings DateJul 15, 2026
Next Earnings DateOct 19, 2026
Ex-Dividend Date―
Financial Position
Hyundai Pharmaceutical Co., Ltd. as a current ratio of 1.13, with Debt / Equity ratio of 38.98%
Current Ratio1.13
Quick Ratio0.68
Debt to Market Cap0.52
Net Debt to EBITDA6.28
Interest Coverage Ratio1.75
Taxes
In the past 12 months, Hyundai Pharmaceutical Co., Ltd. has paid -209.50M in taxes.
Income Tax-209.50M
Effective Tax Rate-0.09
Enterprise Valuation
Hyundai Pharmaceutical Co., Ltd. EV to EBITDA ratio is 18.91, with an EV/FCF ratio of -30.32.
EV to Sales0.75
EV to EBITDA18.91
EV to Free Cash Flow-30.32
EV to Operating Cash Flow-1.16K
Balance Sheet
Hyundai Pharmaceutical Co., Ltd. has ₩18.72B in cash and marketable securities with ₩49.91B in debt, giving a net cash position of -₩31.20B billion.
Cash & Marketable Securities₩18.72B
Total Debt₩49.91B
Net Cash-₩31.20B
Net Cash Per Share-₩974.85
Tangible Book Value Per Share₩2.86K
Margins
Gross margin is 35.83%, with operating margin of 1.72%, and net profit margin of 1.31%.
Gross Margin35.83%
Operating Margin1.72%
Pretax Margin1.20%
Net Profit Margin1.31%
EBITDA Margin3.95%
EBIT Margin1.72%
Analyst Forecast
The average price target for Hyundai Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast12.04%
EPS Growth Forecast―